Veille Scientifique

Patrice PIENKOWSKI
Coordinateur

 Après 3 ans de bons et loyaux services, la veille scientifique va s’arrêter ; voici les derniers articles sélectionnés à votre intention.
 
Nous avons pris cette décision difficile suite au constat d’un investissement très important pour un service rendu finalement incertain, comme l’attestent les statistiques de fréquentation de la rubrique sur ce site. 
 
Je remercie tous ceux et celles qui se sont investis dans la durée pour assurer la réussite du projet, à commencer par les responsables des groupes de veille : Emmanuel Coron (Endoscopie), Roger Faroux (Cancérologie), Pauline Jouët (Gastro-entérologie et proctologie), Stéphane Nahon (MICI), Vinciane Rebours (Pancréatologoie) et Christine Silvain (Hépatologie), mais aussi et surtout, tous les veilleurs anonymes pour la grande qualité de leur travail, leur compétence et leur persévérance.
Le travail de veille bibliographique ne disparait pas complètement malgré tout, grâce aux GastroScoops dont la fréquence va augmenter avec un objectif de diffusion hebdomadaire ; il s’agit d’un travail rédactionnel différent avec une analyse d’article plus approfondie et structurée, porteur de message important.

Restez donc fidèles à ces rubriques et visitez régulièrement le site de la SNFGE toujours très riche d’enseignements et d’informations.

Très cordialement.

Dr Patrice PIENKOWSKI

 

Six groupes animés par un responsable se chargent de ce travail tous les mois :

Cancers Endoscopie

Foie/
VB/
Addicto

Gastro/
Procto/

Nutrition
MICI Pancréas
A. LIEVRE V. VALANTIN I. ROSA P. JOUET S. NAHON V. REBOURS

V. HAUTEFEUILLE
N. WILLIET
N. FARES
Y. TOUCHEFEU

A. CULETTO
Y. LEBALEUR
G. PERROD
V. VALANTIN

C. BARRAULT
P. DUKAN
N. GANNE-CARRIE
PE. RAUTOU

H. DAMON
T. HIGUERO
V. de PARADES
F. ZERBIB

V. ABITBOL
P. FAURE
M. FUMERY
D LAHARIE
P. SEKSIK

M. CAMUS-DUBOC
E. GELSI
L. de MESTIER


Nous espérons de ce nouvel outil qu’il vous aide à accéder rapidement et sélectivement aux données nouvelles de notre discipline selon vos sujets d’intérêt, qu’ils soient larges ou très spécifiques.

Revuetrier par ordre croissant Titre Date Coup de coeur Thématique
Clinical Gastroenterology and Hepatology Association Between Circulating Levels of C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease. juin. 16 2 ♥ MICI
Clinical Gastroenterology and Hepatology Colonic MicroRNA Profiles, Identified by a Deep Learning Algorithm, That Predict Responses to Therapy of Patients With Acute Severe Ulcerative Colitis avr. 19 3 ♥ MICI
Clinical Gastroenterology and Hepatology Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease. mar. 17 3 ♥ MICI
Clinical Gastroenterology and Hepatology Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study oct. 16 3 ♥ MICI
Clinical Gastroenterology and Hepatology Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease. juin. 16 3 ♥ MICI
Clinical Gastroenterology and Hepatology Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis. avr. 19 3 ♥ MICI
Clinical Gastroenterology and Hepatology Factors That Predict High Health Care Utilization and Costs for Patients With Inflammatory Bowel Diseases. mar. 17 3 ♥ MICI
Clinical Gastroenterology and Hepatology Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. oct. 16 3 ♥ MICI
Clinical Gastroenterology and Hepatology Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study. juil. 17 2 ♥ Pancréas/Voies biliaires
Clinical Gastroenterology and Hepatology Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled Trials déc. 15 3 ♥ MICI
Clinical Gastroenterology and Hepatology Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer aoû. 18 2 ♥ Pancréas/Voies biliaires
Clinical Gastroenterology and Hepatology Surgical Interventions and the Use of Device-Aided Therapy for the Treatment of Fecal Incontinence and Defecatory Disorders. déc. 17 4 ♥ Colo-proctologie
Inflammatory Bowel Diseases 2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial mai. 17 2 ♥ MICI
Inflammatory Bowel Diseases Update on the Natural Course of Fistulizing Perianal Crohn's Disease in a Population-Based Cohort. oct. 18 3 ♥ Coloproctologie
Inflammatory Bowel Diseases Defining the Most Appropriate Delivery Mode in Women with Inflammatory Bowel Disease: A Systematic Review. mai. 17 4 ♥ Coloproctologie
Inflammatory Bowel Diseases Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Cro sep. 17 3 ♥ MICI
Inflammatory Bowel Diseases Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab oct. 17 4 ♥ MICI
Inflammatory Bowel Diseases Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy. mai. 16 4 ♥ MICI
Inflammatory Bowel Diseases Comparison of Health Care Utilization and Costs Between Patients with Perianal Fistulizing Crohn's Disease Treated with Biologics with or Without Previous Seton Placement. oct. 17 4 ♥ Coloproctologie
Inflammatory Bowel Diseases Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Jan. 17 2 ♥ MICI
Inflammatory Bowel Diseases Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease juil. 17 3 ♥ MICI
Inflammatory Bowel Diseases The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. fév. 17 2 ♥ MICI
Inflammatory Bowel Diseases Systematic Review and Meta-analysis: Adalimumab Monotherapy Versus Combination Therapy with Immunomodulators for Induction and Maintenance of Remission and Response in Patients with Crohn’s Disease aoû. 17 3 ♥ MICI
Inflammatory Bowel Diseases Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis. avr. 16 4 ♥ MICI
Inflammatory Bowel Diseases Preoperative Use of Methotrexate and the Risk of Early Postoperative Complications in Patients with Inflammatory Bowel Disease aoû. 16 3 ♥ Intestin/Nutrition/Troubles fonctionnels

Pages